Immunome Provides Organizational Update: Appoints Richard Baron to its Board of Directors and Sandra Stoneman as Chief Legal Officer and Corporate Secretary
EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics, with a focus on oncology and infectious diseases including COVID-19, today announced the recent appointments of Richard Baron to Immunome’s Board of Directors and as Audit Committee Chair, and Sandra Stoneman, Esq. as Chief Legal Officer and Corporate Secretary. The company also today announced that its President and Chief Executive Officer, Purnanand Sarma, Ph.D. is the recipient of TiE Boston’s 2020 Lifetime Achievement Award. The award recognizes individuals who have made invaluable contributions in the fields of science, business and entrepreneurship.
“I am thrilled to welcome Richard and Sandra to the Immunome team as we accelerate our efforts in discovering novel antibodies and advancing our lead programs into the clinic,” said President and CEO, Purnanand Sarma, Ph.D. “The combination of their expertise and experience will be invaluable in supporting Immunome’s growth.” He further stated, “I am also honored to receive TiE Boston’s 2020 Lifetime Achievement Award and very much appreciate the opportunity to continue to work with TiE in driving innovation and fostering next generation entrepreneurs.”
Richard Baron has over 30 years of experience as an advisor to companies in the pharmaceutical, biotechnology and medical device industries and as a Chief Financial Officer. He was previously the Chief Financial Officer of Zynerba Pharmaceuticals (Nasdaq: ZYNE), Globus Medical (NYSE: GMED), Avid Radiopharmaceuticals, Animas Corporation (Nasdaq: PUMP) and others. Baron was a practicing certified public accountant, beginning his career in audit and tax services at Coopers & Lybrand and Arthur Young. He received his B.S. in economics at The Wharton School of the University of Pennsylvania. Baron’s background and experience advising life sciences companies and in finance and accounting added significantly to the Board’s skills in these areas.
Sandra Stoneman, Esq. is a seasoned attorney, with more than 20 years of experience advising high-growth companies in the life sciences and technology sectors. Prior to joining Immunome, Stoneman was an attorney at Duane Morris, leading the Firm’s life sciences practice group. She has received numerous accolades for her transactional work in the life sciences field, including being continuously listed in U.S. News/Best Lawyers, Chambers USA and LMG Life Sciences. Stoneman received her J.D. from Temple University School of Law and her B.A. from the State University of New York at Binghamton.
About Immunome, Inc.
Immunome is a biopharmaceutical company utilizing our proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated with an initial focus on oncology and infectious diseases, including COVID-19. Immunome’s proprietary discovery platform identifies novel therapeutic antibodies and their targets by leveraging highly educated components of the immune system, memory B cells, from patients whose bodies have learned to fight off their disease.
Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements” intended to qualify for the “safe harbor” from liability established by the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding Immunome’s beliefs and expectations regarding the advancement of its oncology and COVID-19 therapeutic antibody programs, execution of its clinical and strategic plans, anticipated upcoming milestones for IMM-BCP-01 and IMM‐ONC‐01, including expectations regarding therapeutic potential and benefits thereof, and IND filings. Forward-looking statements may be identified by the words “anticipate,” believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “may,” “will,” “could,” “should,” “seek” and similar expressions. Forward-looking statements are based on Immunome’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with: the impact of the COVID-19 pandemic on Immunome’s business, operations, strategy, goals and anticipated milestones, Immunome’s ability to execute on its strategy including with respect to the timing of IND filings, Immunome’s ability to fund operations, as well as those risks and uncertainties set forth more fully under the caption “Risk Factors” in the final prospectus dated October 1, 2020 and filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, with the United States Securities and Exchange Commission (SEC) and elsewhere in Immunome’s filings and reports with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Immunome undertakes no duty to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law.